

In the claims:

Claims 1-28 Cancelled

29. (currently amended) A method for delivery of a pharmaceutical composition to gastrointestinal or genitourinary cells to treat or prevent a pathologic condition which comprises contacting the intended site of delivery of said pharmaceutical composition with an agent adequate to cause a temporary disruption of the mucosal lining covering said gastrointestinal or genitourinary cells; and

(b) concurrently or subsequent to said contacting of step (a), contacting said gastrointestinal or genitourinary cells with said pharmaceutical composition, wherein said pharmaceutical composition comprises an adenoviral vector comprising a nucleic acid encoding an antigen derived by HSV-2; whereby expression of said antigen induces an immune response in said recipient specific to said antigen, and wherein said method vaccinates said recipient such that the onset o f infection by HSV-2 is inhibited or prevented upon challenge to recipient by HSV-2.

30. (Cancelled)

31. (Cancelled)

32. (Cancelled)